Literature DB >> 21489090

Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants.

R Gattringer1, H Winkler, S Roedler, P Jaksch, H Herkner, H Burgmann.   

Abstract

A combined schedule of 7-valent pneumococcal conjugate vaccine (PCV7) followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) was evaluated retrospectively in 26 adult recipients of heart or lung transplants. PCV7 was immunogenic in these patients but there appeared to be no benefit from the additional PPV23 dose.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21489090     DOI： 10.1111/j.1399-3062.2011.00628.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN： 1398-2273            Impact factor:   2.228


  6 in total

1.  Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.

Authors:  Selma Tobudic; Veronika Plunger; Gere Sunder-Plassmann; Markus Riegersperger; Heinz Burgmann
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

Review 2.  Vaccination strategies in patients with solid organ transplant: evidences and future perspectives.

Authors:  Youn Jeong Kim; Sang Il Kim
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

3.  Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients.

Authors:  Thijs W Hoffman; Bob Meek; Ger T Rijkers; Jan C Grutters; Diana A van Kessel
Journal:  Transplant Direct       Date:  2020-05-21

Review 4.  Bacterial infections in lung transplantation.

Authors:  Margaret McCort; Erica MacKenzie; Kenneth Pursell; David Pitrak
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 3.005

Review 5.  Serologic vaccination response after solid organ transplantation: a systematic review.

Authors:  Isabella Eckerle; Kerstin Daniela Rosenberger; Marcel Zwahlen; Thomas Junghanss
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

Review 6.  A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older.

Authors:  A Steens; D F Vestrheim; I S Aaberge; B S Wiklund; J Storsaeter; M A Riise Bergsaker; K Rønning; E Furuseth
Journal:  Epidemiol Infect       Date:  2014-06-16       Impact factor: 4.434
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.